Procter & Gamble Hygiene & Health Care Ltd. (PGHH) AI Stock Analysis

• Market Cap: ₹443.55B
• Dividend Yield: 1.97%
• Average Volume (3M): 576.00
• Price to Earnings (P/E): 53.5
• Beta (1Y): 0.37
• Revenue Growth: 7.85%
• EPS Growth: 12.60%
• Country: IN
• Employees: 439
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 59.17
• Shares Outstanding: 32,460,735
• 10 Day Avg. Volume: 666
• 30 Day Avg. Volume: 576
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹14,603.00
• Price Target Upside: 6.87% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 70 Outperform
• Price Target: ₹14,603.00 ▲(6.87% Upside)

The overall stock score of 70 reflects strong financial performance, which is the most significant factor, supported by a solid balance sheet and efficient cash flow management. Technical analysis indicates a neutral trend with potential for upward movement. However, the high P/E ratio suggests the stock may be overvalued, which slightly offsets the positive financial performance.

Procter & Gamble Hygiene & Health Care Ltd. Business Overview & Revenue Model

Company Description

Procter & Gamble Hygiene and Health Care Limited manufactures and sells branded packaged fast-moving consumer goods in the feminine care and healthcare businesses in India and internationally. The company provides health care products, including ointments and creams, cough drops, and tablets; and hygiene products, such as feminine hygiene and other skin care hygiene products, as well as feminine care pads. It also offers baby care products comprising nappies, pants, and baby wipes; laundry products; hair care products; home care products; and oral care products. The company offers its products under the Vicks, Whisper, Pampers, Ariel, Tide, Gillette, Head & Shoulders, Herbal Essences, Pantene, Ambi Pur, Oral-B, Olay, and Old Spice brand names. It sells its products through retail operations, including mass merchandisers, as well as grocery, membership club, drug, department, and high frequency stores. The company was incorporated in 1964 and is based in Mumbai, India. Procter & Gamble Hygiene and Health Care Limited is a subsidiary of Procter & Gamble Overseas India BV.

How the Company Makes Money

Procter & Gamble Hygiene & Health Care Ltd. generates revenue through the sale of its consumer products, primarily in the personal health and hygiene categories. Its key revenue streams include the sale of feminine care products, like sanitary napkins and tampons, and health care products, such as Vicks. The company's earnings are significantly influenced by its strong brand recognition, extensive distribution network, and strategic marketing efforts. PGHH leverages Procter & Gamble's global capabilities in research and development to innovate and maintain a competitive edge in the market. Additionally, partnerships with retailers and distributors play a crucial role in expanding its market reach and driving sales.

Procter & Gamble Hygiene & Health Care Ltd. Financial Statement Overview

Summary

Procter & Gamble Hygiene & Health Care Ltd. exhibits strong financial health across all verticals. The income statement reflects robust profitability and growth, while the balance sheet highlights a conservative financial structure with low leverage. Cash flow metrics indicate efficient cash generation and utilization, although some volatility in free cash flow growth is noted. Overall, the company is well-positioned for continued stability and growth.

Income Statement

Procter & Gamble Hygiene & Health Care Ltd. demonstrates strong profitability with a consistent gross profit margin above 55% and a net profit margin nearing 19%. The company has shown steady revenue growth, with a 4.26% increase in the latest period. EBIT and EBITDA margins are robust, indicating efficient operations and cost management.

Balance Sheet

The company maintains a very low debt-to-equity ratio, reflecting minimal leverage and financial risk. Return on equity is impressive, indicating effective use of shareholder funds to generate profits. The equity ratio suggests a solid capital structure with a significant portion of assets financed by equity.

Cash Flow

Operating cash flow is strong, covering net income comfortably. Free cash flow has shown significant growth, although there are fluctuations in free cash flow growth rates. The company efficiently converts net income into free cash flow, supporting its financial flexibility.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	43.02B	44.99B	42.06B	39.05B	39.01B	35.70B
Gross Profit	25.84B	25.48B	25.76B	22.42B	17.17B	22.42B
EBITDA	12.11B	12.11B	10.22B	8.98B	8.43B	9.18B
Net Income	7.18B	8.49B	6.75B	6.78B	5.76B	6.52B
Balance Sheet
Total Assets	17.55B	17.55B	18.59B	21.37B	16.81B	16.33B
Cash, Cash Equivalents and Short-Term Investments	5.16B	5.16B	5.74B	9.64B	6.25B	6.48B
Total Debt	23.20M	23.20M	30.80M	40.30M	51.00M	34.70M
Total Liabilities	10.18B	10.18B	10.84B	11.91B	9.44B	9.18B
Stockholders Equity	7.37B	7.37B	7.75B	9.46B	7.38B	7.14B
Cash Flow
Free Cash Flow	5.15B	5.63B	4.26B	7.81B	5.23B	8.32B
Operating Cash Flow	5.73B	6.18B	4.71B	8.26B	5.73B	8.63B
Investing Cash Flow	-525.30M	-586.30M	10.60M	-99.10M	-268.50M	69.40M
Financing Cash Flow	-12.19B	-6.66B	-8.62B	-4.77B	-5.69B	-11.06B

Procter & Gamble Hygiene & Health Care Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13664.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHH, the sentiment is Positive. The current price of 13664.1 is above the 20-day moving average (MA) of 13438.78, above the 50-day MA of 13301.70, and below the 200-day MA of 13781.52, indicating a neutral trend. The MACD of 96.85 indicates Negative momentum. The RSI at 57.70 is Neutral, neither overbought nor oversold. The STOCH value of 62.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PGHH.

Procter & Gamble Hygiene & Health Care Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZYDUSWELL	73 Outperform	₹153.21B	46.84	6.12%	0.25%	10.63%	7.53%
PGHH	70 Outperform	₹443.55B	53.53	―	1.97%	7.85%	12.60%
COLPAL	69 Neutral	₹604.66B	43.39	86.32%	2.29%	2.12%	-1.45%
EMAMILTD	66 Neutral	₹244.94B	29.77	29.93%	1.43%	4.06%	10.78%
GILLETTE	66 Neutral	₹310.65B	55.14	54.43%	1.17%	13.05%	38.04%
DABUR	58 Neutral	₹886.31B	49.73	16.37%	1.60%	-0.03%	-5.22%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%

Procter & Gamble Hygiene & Health Care Ltd. Corporate Events

Procter & Gamble Hygiene and Health Care Holds 61st AGM Virtually

Procter & Gamble Hygiene and Health Care Limited held its 61st Annual General Meeting on September 4, 2025, via video conferencing. The meeting was chaired by Mr. Gurcharan Das, due to the absence of the usual chairperson, Mr. Chittranjan Dua. The AGM was conducted in compliance with guidelines from the Ministry of Corporate Affairs and SEBI, with key board members and management representatives present. The meeting facilitated the discussion of the company’s annual report and other statutory matters, reflecting the company’s adherence to regulatory requirements and its commitment to transparent communication with shareholders.

P&G Hygiene and Health Care Re-Submits Q2 Financial Results

Procter & Gamble Hygiene and Health Care Limited has re-submitted its unaudited financial results for the quarter ending June 30, 2025, due to the previous submission not being in a machine-readable format as required by the exchange. This update ensures compliance with exchange requirements and maintains transparency with stakeholders regarding the company’s financial performance.

Procter & Gamble Approves Q2 2025 Financial Results

Procter & Gamble Hygiene and Health Care Limited announced the approval of its unaudited financial results for the quarter ending June 30, 2025, during a board meeting. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and operational health, potentially impacting its market positioning and investor confidence.

Procter & Gamble Re-appoints Independent Director for Five-Year Term

Procter & Gamble Hygiene and Health Care Limited has announced the re-appointment of Mr. Chittranjan Dua as an Independent Director for a five-year term starting August 25, 2025. This decision, approved by the Board of Directors and subject to shareholder approval, underscores the company’s commitment to maintaining experienced leadership. Mr. Dua meets all regulatory criteria for independence and is not disqualified from holding the director position, ensuring compliance with corporate governance standards.